Israeli biopharmaceutical company: UroGen Pharma (URGN)(2004)

UroGen Pharma Ltd. (NASDAQ:URGN) was founded in 2004. It is an Israeli company. It was previously headquartered in Ra’anana, Israel, and now headquartered in New York City, New York, USA, with 88 full-time employees (9/30/2019) , Is a clinical stage biopharmaceutical company focusing on the development of urological pathology therapies.

UroGen Pharma

UroGen Pharma (URGN):

Candidate products of UroGen Pharma Ltd. include:

  1. MitoGel and VesiGel (UGN-101 and UGN-102) are chemotherapeutic generic drugs Mitomycin C preparations (a proprietary formulation of the chemotherapy drug mitomycin), currently only used as adjuvants or supplements for the treatment of urothelial cancer in aqueous preparations After treatment.
  2. UroGen Pharma is developing a chemical anti-inflammatory agent candidate product designed for non-surgical removal of tumors to treat various forms of non-muscular invasive urothelial cancer, including mild upper urothelial cancer and mild bladder cancer.

UroGen Pharma Ltd. has signed a license agreement with Allergan Pharmaceuticals International Limited to develop and commercialize drugs containing RTGel and Clostridial toxin.

UroGen Pharma (URGN) investment:

UroGen Pharma Ltd. (NASDAQ:URGN) went public on 5/4/2017 together with Biohaven Pharmaceutical Holding Company (BHVN) and listed on NASDAQ. The issue price was US$13. It issued 4,473,373 shares and raised US$58,153,849.00. , Stock code: URGN.

Notify of
Inline Feedbacks
View all Intels

Bank holding company: Provident Financial Holdings (PROV) (1956)

Swedish furniture, kitchen appliances, home accessories retailer: IKEA (1943)